TMA-230(TMA-230) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用方式

抑制剂

作用机制

细胞壁抑制剂

治疗领域

感染

在研适应症-

非在研适应症

细菌感染

原研机构

Novartis Pharma AG

在研机构-

非在研机构

Novartis Pharma AG

Takeda Pharmaceutical Co., Ltd.

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C13H12N2O4S

InChIKeyBFYPGIMLKFZWEI-UTMSNSNXSA-N

CAS号113141-75-6

关联

100 项与 TMA-230 相关的临床结果

登录后查看更多信息

100 项与 TMA-230 相关的转化医学

登录后查看更多信息

100 项与 TMA-230 相关的专利（医药）

登录后查看更多信息

5

项与 TMA-230 相关的文献（医药）

2002-08-01·Antimicrobial Agents and Chemotherapy2区 · 医学

Extrusion of Penem Antibiotics by Multicomponent Efflux Systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa

2区 · 医学

Article

作者: Nishino, Takeshi ; Okamoto, Kiyomi ; Gotoh, Naomasa

ABSTRACT The high intrinsic penem resistance of Pseudomonas aeruginosa is due to the interplay among the outer membrane barrier, the active efflux system MexAB-OprM, and AmpC β-lactamase. We studied the roles of two other efflux systems, MexCD-OprJ and MexXY-OprM, in penem resistance by overexpressing each system in an AmpC- and MexAB-OprM-deficient background and found that MexAB-OprM is the most important among the three efflux systems for extrusion of penems from the cell interior.

2001-07-01·Antimicrobial Agents and Chemotherapy2区 · 医学

Pseudomonas aeruginosa Reveals High Intrinsic Resistance to Penem Antibiotics: Penem Resistance Mechanisms and Their Interplay

2区 · 医学

Article

作者: Nishino, Takeshi ; Okamoto, Kiyomi ; Gotoh, Naomasa

1996-01-01·Journal of Antimicrobial Chemotherapy2区 · 医学

Comparative stability of carbapenem and penem antibioties to human recombinant dehydro-peptidase-I

2区 · 医学

Letter

作者: S. Mitsuhashi ; T. Nasu ; M. Mori ; T. Nishihara ; M. Hikida

The authors demonstrate that three new carbapenems (BO-2727, DX-8739, S-4661) and one new penem (AMA-3176) are relatively stable to human recombinant dehydropeptidase-I in vitro.The rank order of the stability against hydrolysis by the enzyme was: BO-2727 > AMA-3176 > S-4661 > DX-8739 >> imipenem.The next steps will be to determine the in vivo stability of the antibiotics and to evaluate their clin. usefulness.

100 项与 TMA-230 相关的药物交易

登录后查看更多信息